Janssen Pharmaceutica Inc.
www.janssen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Janssen Pharmaceutica Inc.
Empress Looks To The Body’s Internal Chemistry For Drug Leads
Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.
Japan Nods Include Torii's Vtama, Skyrizi In New Uses
Japan issues approval recommendations in new indications, including Torii's Vtama in atopic dermatitis and AbbVie's Skyrizi in ulcerative colitis. Separately, filing requirements for the use of concomitant therapies have been revised.
Janssen’s Stelara May Be Medicare Price Negotiation Savings Star
New research is gauging how much savings CMS may see on the prices of the first 10 drugs selected for negotiation.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice